Interleukin‐13 promoter gene polymorphism ‐1112C/T is associated with the systemic form of mastocytosis

Background:  Mastocytosis is a heterogenous disease involving mast cells (MC) and their progenitors. Cutaneous and systemic variants of the disease have been reported. In contrast to cutaneous mastocytosis (CM), patients with systemic mastocytosis (SM) are at risk to develop disease progression or a nonMC‐lineage haematopoietic neoplasm. Little is known, however, about factors predisposing for the development of SM. One factor may be cytokine regulation of MC progenitors.

[1]  L. Scott,et al.  Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. , 2007, Blood.

[2]  M. Triggiani,et al.  Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria , 2007, European journal of clinical investigation.

[3]  P. Valent,et al.  Diagnostic and Subdiagnostic Accumulation of Mast Cells in the Bone Marrow of Patients with Anaphylaxis: Monoclonal Mast Cell Activation Syndrome , 2006, International Archives of Allergy and Immunology.

[4]  C. Brightling,et al.  Mast cells express IL‐13Rα1: IL‐13 promotes human lung mast cell proliferation and FcɛRI expression , 2006, Allergy.

[5]  S. Weiland,et al.  IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. , 2006, The Journal of allergy and clinical immunology.

[6]  K. Sotlar,et al.  Mastocytosis: Pathology, genetics, and current options for therapy , 2005, Leukemia & lymphoma.

[7]  Anjana Rao,et al.  Role of NFAT Proteins in IL13 Gene Transcription in Mast Cells*♦ , 2004, Journal of Biological Chemistry.

[8]  D. Metcalfe,et al.  The biology of Kit in disease and the application of pharmacogenetics. , 2004, The Journal of allergy and clinical immunology.

[9]  P. Valent,et al.  Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. , 2004, The Journal of allergy and clinical immunology.

[10]  H. Malling,et al.  Association between an interleukin-13 promoter polymorphism and atopy. , 2003, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[11]  B. Longley,et al.  Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. , 2003, Experimental hematology.

[12]  U. Lass,et al.  One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. , 2003, The American journal of pathology.

[13]  P. Valent,et al.  Kit and c-kit Mutations in Mastocytosis: A Short Overview with Special Reference to Novel Molecular and Diagnostic Concepts , 2002, International Archives of Allergy and Immunology.

[14]  D. Postma,et al.  Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. , 2001, American journal of respiratory cell and molecular biology.

[15]  D. Metcalfe,et al.  Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin. , 2001, Blood.

[16]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[17]  J. Kantelip,et al.  Autocrine regulation of cord blood-derived human mast cell activation by IL-10. , 2001, The Journal of allergy and clinical immunology.

[18]  P. Valent,et al.  Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. , 2001, Leukemia research.

[19]  P. Valent,et al.  Mutation analysis of C‐KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis , 2001, British journal of haematology.

[20]  K. Hartmann,et al.  Mastocytosis: recent advances in defining the disease , 2001, The British journal of dermatology.

[21]  S. Weiland,et al.  A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. , 2000, The Journal of allergy and clinical immunology.

[22]  E. Groot,et al.  An IL-13 promoter polymorphism associated with increased risk of allergic asthma , 1999, Genes and Immunity.

[23]  D. Heitjan,et al.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Pawankar,et al.  Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells. , 1998, The Journal of allergy and clinical immunology.

[25]  Möller,et al.  Comparative cytokine gene expression: regulation and release by human mast cells , 1998, Immunology.

[26]  Laura H. Tang,et al.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.

[27]  B. Zweiman,et al.  The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. , 1995, The Journal of clinical investigation.

[28]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Ashman,et al.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.

[30]  L. Ashman,et al.  IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. , 1991, Journal of immunology.

[31]  D. Metcalfe,et al.  Classification and diagnosis of mastocytosis: current status. , 1991, The Journal of investigative dermatology.

[32]  T. Mosmann,et al.  Interleukin 10: a novel stimulatory factor for mast cells and their progenitors , 1991, The Journal of experimental medicine.

[33]  C. Uyttenhove,et al.  Mast cell growth‐enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9) , 1990, European journal of immunology.

[34]  H. S. Earl,et al.  Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. , 1987, The New England journal of medicine.

[35]  T. Honjo,et al.  Interleukin 4 as an essential factor for in vitro clonal growth of murine connective tissue-type mast cells , 1987, The Journal of experimental medicine.

[36]  J. Ihle,et al.  Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity. , 1983, Journal of immunology.

[37]  K. Lennert,et al.  Mast cells and mast cell neoplasia: a review * , 1979, Histopathology.

[38]  M. Kaghad,et al.  Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. , 1993, Nature.

[39]  G. Dewald,et al.  Establishment of an immature mast cell line from a patient with mast cell leukemia. , 1988, Leukemia research.